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Erythropoietin and iron. Serum ferritin concentration is most aggregated form as hemosiderin. Ferritin is formed as an
informative in estimating the amount of storage iron available approximately spherical protein shell where, in its cavity,
for a particular individual. The serum transferrin receptor con-
relatively large amounts of polynuclear hydrous Fe(III)centration, in contrast to serum ferritin, provides direct infor-
oxide phosphate can be stored.mation about any deficit in the adequacy of iron supply to the
erythropoiesis. The combination of serum transferrin receptor Much of the body’s iron reserve is located in the cells
and serum ferritin provides complete information about stor- of the macrophage-monocyte system, especially in the
age and functional iron compartments. Using this combination
liver, spleen, bone marrow, and skeletal muscle. Ironalong with the hemoglobin concentration, it is possible to define
stored in these sites can be mobilized and distributedthe iron nutritional status completely. Inflammatory conditions
as well as parenteral iron administration interfere, however, via plasma transferrin to wherever it is needed. In the
with the direct and quantitative ferritin to storage iron relation- circulation, a tiny quantity of ferritin is found, which,ship and, therefore, have to be considered carefully with respect
in normal and iron-depleted subjects, is in close directto diagnostic purposes. The diagnostic use of the serum trans-
ferrin receptor is presently limited because of limitations in meth- correlation with the total body iron reserve [1].
odology and definition (standardization) of reference ranges.
SERUM FERRITIN
Ferritin and the transferrin receptor are important mark- There is a good correlation between the small amount
ers of two different compartments of iron metabolism.
of ferritin found in the serum (serum ferritin) and bodyFerritin is the major iron storage protein. In the physi-
iron stores [1, 2].ology of iron metabolism ferritin has the important role
Serum ferritin concentrations are relatively stable inof maintaining iron in a soluble, nontoxic, and biologi-
healthy persons. In patients with iron deficiency, serumcally useful form. It has the capacity to sequester vast
ferritin concentrations are less than 12 mg/liter. A reduc-quantities of iron, and acts as a buffer against normal
tion of the level of reticuloendothelial stores is the onlyphysiological variations in the iron requirements of tissues.
common cause of a low serum ferritin concentration.The transferrin receptor is responsible for the media-
This is the key to the use of the serum ferritin assay intion of cellular uptake of transferrin-bound iron. The
clinical practice [2, 3].receptor is predominantly present on the cell surface of
erythroid progenitors. There is an increased synthesis
of this receptor by erythroid cells under conditions of
NORMAL VALUESenhanced erythropoiesis, as well as during reduced iron
supply to the bone marrow. In its truncated and in the The normal range for serum ferritin concentration in
circulation shedded form, the transferrin receptor may healthy subjects, based on hemoglobin as the selection
be regarded as a marker for the adequacy of iron supply criteria, was 15 to 300 mg/liter [2]. By using hemoglobin
to the erythroid marrow. concentrations, histochemical bone marrow iron grading
and/or measurement of intestinal iron absorption as indi-
FERRITIN cators of a normal body iron status, however, normal
values of 59 mg/liter (95% confidence range, 20 to 170Ferritin is a protein specialized for the storage of iron
mg/liter) were observed in 44 healthy females and 91 mg/in tissues. Any iron that is surplus to immediate func-
liter (32 to 264 mg/liter) for 67 healthy males, respectivelytional needs is stored in the tissue in ferritin or in its
[1]. These normal ranges are in good accordance with
findings of other groups [4, 5]. Significant differences inKey words: ferritin, iron storage, erythropoiesis, hemoglobin, trans-
ferrin receptor. the ferritin concentration between men and women are
consistent with the known difference in storage iron be- 1999 by the International Society of Nephrology
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iron levels of approximately 20 g (Fig. 2). For clinical
purposes, this variation must be considered when the
amount of storage iron is calculated from serum ferritin
measurements.
RED CELL FERRITIN
The circulating erythrocytes contain a tiny residue of
that ferritin present in its nucleated precursors in the
bone marrow. The mean concentration in erythrocytes
of the peripheral blood is approximately 10 ag/cell (10218
g/cell), measured with antibodies to H-type ferritin. The
general red cell ferritin levels reflect the iron supply to
the erythroid marrow and tend to vary inversely with
the red cell protoporphyrin [9]. In untreated genetic
hemochromatosis, red cell ferritin content is approxi-
Fig. 1. Changes in serum ferritin concentration in healthy normal sub- mately 70 times the normal mean. Red cell ferritin was
jects as a function of age (according to Dallman et al [58]; used with shown to reflect liver parenchymal cell iron concentra-
permission).
tions [10]. High levels of red cell ferritin are also found in
thalassemia, megaloblastic anemia, and myelodysplastic
syndromes, presumably indicating a disturbance of ery-
throid iron metabolism in these conditions [2]. Despitetween the sexes (Fig. 1). In older men and women the
these specific diagnostic advantages, the assay of redmean concentrations are similar, while in children serum
cell ferritin has little routine application thus far, mainly
ferritin concentrations are generally lower than in adults.
because it is necessary to have fresh blood in order to
prepare red cells free of white cells, which have much
higher ferritin levels [2].CORRELATION TO IRON STORES
A good correlation has been found between serum
SERUM FERRITIN AND INFLAMMATIONferritin and storage iron, mobilized by phlebotomy, stain-
able iron in the bone marrow, and the concentration of Inflammation and neoplasia are associated with a sig-
both nonhem-iron and ferritin in the bone marrow [2]. nificant rise in serum ferritin levels [11–16]. The response
of serum ferritin levels to inflammation was found toThere is also a significant inverse correlation between
parallel the acute phase plasma proteins, haptoglobin,intestinal iron absorption and the logarithm of the serum
and C-reactive protein [11, 14], suggesting that serumferritin concentration [4, 6].
ferritin behaves as an acute phase reactant [17]. TheThis suggests that a close relationship exists between
degree of rise in serum ferritin concentration is, however,the total amount of storage iron and serum ferritin con-
influenced by the iron status of the patient [14]. Serumcentration in normal individuals.
ferritin most probably is a secretory protein because,This correlation, however, does not exist in patients
in contrast to intracellular tissue ferritin, most of thewith iron overload caused by genetic hemochromatosis.
circulating ferritin is glycosilated, representing the minorCalculations derived from the correlation of serum ferri-
fraction of intracellular ferritin synthesized on mem-tin with iron stores as determined by repeated phlebot-
brane-bound polysomes [18–20].omy suggest that in normal individuals, for each mg/liter
Because of the behavior of ferritin as an acute phase
ferritin there are 8 to 12 mg of storage iron [7, 8]. This
reactant, inflammation can result in a false elevation of
ferritin-to-storage iron ratio, however, does not seem to the ferritin values and can bring ferritin values for pa-
be constant over the entire range from iron deficiency tients with true iron deficiency into the normal range
to heavy iron overload. Normal healthy volunteers with [12]. With active inflammation, plasma levels of ferritin
mobilizable iron stores ranging from 200 mg to 1.8 g can rise sharply in the absence of any change in total
were considered, together with patients with genetic body iron stores. These factors place limitations on the
hemochromatosis (iron stores 890 mg to 20.0 g). The use of serum ferritin as a marker for iron deficiency, for
ferritin-to-storage iron ratio decreased with increasing example, in end-stage renal disease, but it remains the
iron stores. At iron stores below 500 mg, the ratio aver- best available guide to the adequacy of iron stores prior
aged 15 mg storage iron per mg/liter of ferritin and de- to recombinant human erythropoietin (rHuEPO) ther-
apy [21]. Once steady-state erythropoiesis and iron bal-creased to a ratio of 6 mg per mg/liter of ferritin at storage
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Fig. 2. Correlation of storage iron mobilized
by repeated phlebotomy, with serum ferritin
concentration in 69 healthy male subjects (s)
and 71 patients with genetic hemochromatosis
(d) at various clinical stages. Note the direct
and linear relationship in storage iron concen-
trations of less than 2.0 g and the remarkable
changes of the ferritin to storage iron ratio in
storage iron concentration of more than 2.0 g.
ance have been re-established, serum ferritin can again iron deficiency, but may demonstrate an increase in he-
moglobin when i.v. iron is administered. Distinguishingbe used to assess iron stores.
between functional iron deficiency and an inflammatory
iron block is a common clinical problem. The percentage
SERUM FERRITIN AND FUNCTIONAL
of hypochromic red cells does appear to be a reliable
IRON DEFICIENCY
and sensitive indicator for functional iron deficiency and
In otherwise healthy subjects, iron deficiency is consid- has been shown to be helpful in the diagnosis of func-
ered “absolute” when iron stores are depleted or com- tional iron deficiency (Fig. 3) [26, 27]. Normally, there
pletely exhausted, as indicated by serum ferritin concen- are less than 2.5% of red cells with individual cell hemo-
trations below the lower normal limits (mentioned earlier globin of less than 28 pg/dl. Values exceeding 10% are
here). Complete exhaustion of iron stores normally is compatible with functional iron deficiency in rHuEPO-
indicated by serum ferritin concentrations of less than treated patients. This measurement is, however, pres-
12 mg/liter [1] and inappropriate iron delivery to the ery- ently performed as part of routine full blood samples
throid marrow as evidenced by transferrin iron saturation that requires a Technicont H-1, H-2, or H-3 automated
(TISAT) levels below 15% [22]. In the specific situation cell counter (Bayer Diagnostics, Mu¨nchen, Germany),
of chronic renal failure (CRF), absolute iron deficiency which may be not available in many medical centers
has been defined as serum ferritin levels of less than 100 in Europe or the United States [23]. Because of these
mg/liter and TISAT levels of less than 20% [23]. limitations, currently the best tests of iron status are the
Besides the absolute iron deficiency, a different pat- percentage TISAT and the serum ferritin. Although no
tern of iron deficiency can occur when there is a need for single value of TISAT or serum ferritin accurately dis-
a greater amount of iron to support hemoglobin synthesis criminates between CRF patients who are or are not
than can be released from the reticuloendothelial iron functionally iron deficient, available data demonstrate
stores. This situation, which can be caused by stimulation that the lower the TISAT and serum ferritin, the higher
of erythropoiesis by erythropoietin or by limitation of the likelihood that a patient is iron deficient, and the
storage iron release due to inflammatory processes, can higher the TISAT and the serum ferritin, the lower the
occur in the presence of adequate or even increased iron likelihood that a patient is iron deficient [23].
stores. It has been called “functional” or “relative” iron
deficiency [24].
SERUM FERRITIN AND IRON TREATMENTFunctional iron deficiency is a frequent issue associ-
ated with rHuEPO treatment in both renal anemia and Serum ferritin concentrations below the lower levels
of normal ranges always indicate the presence of abso-the anemia of chronic disorders (ACD). It is also com-
monly observed when rHuEPO is used to increase autol- lute iron deficiency and therefore are a clear indication
for iron supplementation. Because the distinction be-ogous blood donation [25]. Patients with this condition
do not meet traditional laboratory criteria for absolute tween absolute and functional iron deficiency in CRF
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Fig. 3. Course of hemoglobin and percentage of hypochromic red cells (A) as well as serum ferritin and saturation of TIBC (B) in a female
patient with severe inflammatory active rheumatoid arthritis treated with recombinant human erythropoietin (150 IU/kg s.c. twice a week) together
with an intravenous iron supply (125 to 200 mg twice a week). Note the development of functional iron deficiency after initiation of EPO treatment
as shown by the inappropriate hemoglobin increase and rise of hypochromic red cells above 10% (left hand side), whereas serum ferritin increased
continuously and the saturation of TIBC remained below 20%. Abbreviations are: OP, start of surgical treatment (knee joint TEP); Recormont,
recombinant human erythropoietin; Ferrlecitt, Fe(III) gluconate; Venofert, iron sucrose complex.
patients, specifically before or during EPO treatment, hemoglobin regeneration takes place. A relevant stable
increase in storage iron, as indicated by increasing ferri-is more crucial, several recent consensus reports have
recommended that serum ferritin should be kept at more tin levels, is observed only when hemoglobin regenera-
tion reaches a steady state. In contrast, after i.v. ironthan 100 mg/liter in order to maintain a sufficient iron
reserve [21, 23, 28]. Most EPO-treated patients require administration (100 to 200 mg/day), serum ferritin in-
creases disproportionally to the amount of storage ironintravenous iron to build up their respective iron stores.
A small percentage of hemodialysis patients as well as present [31, 32]. Therefore, for serum ferritin to be used
as an indicator of the iron stores rebuilt by i.v. ironmany peritoneal dialysis and predialysis patients are also
able to maintain adequate iron stores using only oral supplementation, it should not be determined earlier
than two weeks after the last i.v. iron dose.iron supplements [21, 23, 29]. Patients with initial ferritin
levels of less than 100 mg/liter, however, will almost cer- There is little information available that clearly estab-
lishes the upper limit of safety for serum ferritin in pa-tainly require intravenous iron to support the require-
ments of the marrow during rHuEPO treatment [30]. tients receiving i.v iron therapy. Serum ferritin levels be-
tween 300 and 800 mg/liter have been common in dialysisDuring oral iron administration in therapeutic doses (100
to 200 mg/day) in absolute iron-deficient patients with patients, and there is no evidence that such levels are
associated with adverse iron-mediated effects [23]. Ironunimpaired intestinal iron absorption, the serum ferritin
concentration within the first 5 to 10 days increases up therapy should, however, be used or continued with ex-
treme caution in patients whose serum ferritin is greaterto normal levels and decreases again when increasing
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than 1000 mg/liter or where the TISAT level is above These findings were confirmed in subsequent studies [35,
36, 45].50% [21].
In controlled phlebotomy studies, the receptor does
not increase until iron stores are completely exhausted
SERUM TRANSFERRIN RECEPTOR (Fig. 4) [47]. When serum ferritin fell below 12 mg/liter,
On actively growing human tumor cells, Sutherland the serum receptor increased above normal levels,
et al have found a specific receptor for the iron transport roughly in proportion to the deficit in functional iron.
protein transferrin [33]. By somatic hybrid cell studies,
Goodfellow et al assigned the transferrin receptor (TRF-
CORRELATION TO IRON STORESR) locus to chromosome 3 [34]. The number of trans-
ferrin receptors on the cell surface is directly related to Distinguishing between IDA and ACD remains unsat-
isfactory in some cases. Serum ferritin, serum iron, andthe erythroid activity [35–37].
The transferrin receptor molecule consists of two iden- TISAT are sometimes too low in value to classify the
different forms of anemias. In particular, the combina-tical domains. On each domain, the binding of two mole-
cules of transferrin is possible. Transferrin receptors are tion of ACD and iron deficiency anemia, which is often
seen, for example, in patients suffering from CRF orfound on cell membranes and allow iron-bound trans-
ferrin to enter the cell. In the case of high saturation rheumatoid arthritis, could remain a diagnostic problem
because serum ferritin levels are higher in patients withwith iron, transferrin is bound with a significantly higher
affinity to the binding sites of the receptor [38]. When both IDA and ACD compared with those with absolute
iron deficiency alone. sTRF-R in these special cases canthe iron supply is inadequate, there is an up-regulation
of transferrin receptors to enable the cell to compete distinguish between both forms because elevated sTRF-
R levels are characteristic for IDA regardless of whethermore effectively for iron.
As known with other membrane proteins, a shaded there is chronic inflammation [48]. In contrast, sTRF-R
remains unaffected in patients with anemia caused byform of the transferrin receptor is known. This sTRF-R
is detectable in the blood serum, and it is found as a chronic disorders [49–52]. In patients with anemia of
CRF, Beguin et al demonstrated that sTRF-R could pre-truncated fragment of the transmembrane receptor. The
number of membrane receptors is in proportion to the dict the response to rHuEPO therapy [53]. In this group
of patients, the best response rates were shown whenreceptors found in the circulating blood plasma. In com-
parison to the complete molecule, sTRF-R lacks the the sTRF-R (and fibrinogen) level was low [53]. This
could be because responders to treatment with rHuEPOcytoplasmic and the transmembrane domains [39].
Like serum iron and transferrin, sTRF-R shows a diur- and intravenous iron administration probably show
higher levels of sTRF-R during the therapy interval [54].nal and seasonal pattern in its peak trough differences,
but many authors confirmed that measurement of sTRF-R It was also shown that sTRF-R increases progressively
for a six-week period and reaches a plateau when pa-in serum is a sensitive indicator for both the total erythro-
poiesis and iron deficiency [35–38, 40–43]. tients with CRF are treated with rHuEPO [55].
CONCLUSIONSERUM TRANSFERRIN RECEPTOR ASSAY
Measurement of sTRF-R is based on enzyme-linked One of the major diagnostic problems is to distinguish
iron deficiency from other causes of anemia, that is, ane-immunosorbent essays (ELISA) with monoclonal anti-
bodies against parts of the receptor molecule, and by mia of chronic diseases. Because most of the tissue recep-
tors have been found on the erythroid precursor cell,latex agglutination nephelometric immunoassay [37, 38,
43, 44]. The normal range for serum transferrin receptor the level of sTRF-R measured in serum is directly pro-
portional to erythroid activity and reflects the total bodydepends strongly on the method used for the determina-
tion of the protein [45]. In a study using a monoclonal mass of tissue receptor [36, 38, 41, 56]. The serum ferritin
level and serum transferrin receptor level can portrayELISA technique, the mean value for 82 healthy males
and females was 5.6 mg/liter, and for iron deficiency the entire spectrum of iron deficiency from normal to
severe ID. Unlike serum ferritin, serum transferrin re-anemia it was 18 mg/liter [45]. However, validation of
the different methods is missing thus far, and normal ceptor remains normal in patients with acute or chronic
inflammation or liver disease [47] and appears to bevalues independent from the underlying method are not
available [46]. This is caused by the fact that purified effective in distinguishing iron deficiency anemia from
anemia of chronic disease [49].transferrin receptors were not available, and standard-
ization of the test systems was not possible. This new parameter provides a quantitative measure
of increased erythropoietic activity, for example, abso-In patients suffering from iron-deficiency anemia (IDA),
strictly elevated levels of sTRF-R were reported [37]. lute or functional iron deficiency, and could be a useful
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alternative in distinguishing the associated anemia from
that of chronic disease [56, 57]. Additionally, this param-
eter leads to a more stable measurement than transferrin
saturation and is affected earlier in the development of
functional iron deficiency than traditional hematological
indices such as the erythrocyte protoporphyrin or mean
corpuscular volume.
On the other hand, it must be noted that determination
of sTRF-R using different techniques leads to uncompa-
rable results. Furthermore, the measurement of serum
transferrin receptor is not routinely used in clinical prac-
tice because it is still expensive; it should only carried out
in patients in whom the quantitation of hypochromic red
cells is not available or when the determination of serum
ferritin, serum iron, transferrin, and saturation of trans-
ferrin does not lead to an accurate classification of the
type of anemia.
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